"BNP Paribas Secures €400 Million Financing for Zydus Lifesciences' Acquisition of Amplitude Surgical"

"Ashurst advised BNP Paribas on a €400 million financing to support Zydus Lifesciences Ltd's acquisition of Amplitude Surgical, a company listed on Euronext Paris and controlled by PAI Partners. The financing, arranged and guaranteed by BNP Paribas, aims to enhance Zydus's growth strategy and strengthen its position in the medical and pharmaceutical sectors. The credit facility was finalized in July 2025, and the public offer was approved by the French Financial Markets Authority on September 25, 2025. The Ashurst team in Paris was led by Éric Fiszelson, with support from other associates and counsel."

**Press Release Summary** Ashurst advised BNP Paribas in connection with a €400 million financing aimed at supporting the acquisition of Amplitude Surgical, a company listed on Euronext Paris and controlled by PAI Partners, by Zydus Lifesciences Ltd (Zydus). The €400 million credit facility was finalized at the end of July 2025, and the public offer was approved by the Autorité des marchés financiers (AMF) on September 25, 2025. This approval confirmed the compliance of the simplified public offer project, which may be followed by a mandatory withdrawal if conditions are met. The Ashurst team in Paris was led by partner Éric Fiszelson, assisted by associates Jeffrey Andrélan and Adriana Cristiani from the Global Loan department, as well as partner Nicolas Bombrun, counsel Gaspard Bastien-Thiry, and associate Athénaïs de Sercey from the corporate department.

"BNP Paribas Secures €400 Million Financing for Zydus Lifesciences' Acquisition of Amplitude Surgical"

Read the full story

Cookie Preferences

Strictly Necessary

Analytics & Statistics

Marketing & Ads